ISF35
/ Memgen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 22, 2021
A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL
(clinicaltrials.gov)
- P1b; N=13; Completed; Sponsor: Memgen, LLC; Active, not recruiting ➔ Completed; Phase classification: P1 ➔ P1b
Phase classification • Trial completion • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • CD19 • CD20 • CD5 • FCER2 • TP53
1 to 1
Of
1
Go to page
1